Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1529-0131|65|8|2143-2153

ISSN： 0004-3591

Source： Arthritis & Rheumatism, Vol.65, Iss.8, 2013-08, pp. : 2143-2153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Belimumab: In Systemic Lupus Erythematosus

By Burness Celeste B.   McCormack Paul L.  

Drugs, Vol. 71, Iss. 18, 2011-12 ,pp. : 2435-2444

Adis International

Access to resources Recommend Favorite

Ethinylestradiol/levonorgestrel: Major flares of systemic lupus erythematosus: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1181, 2007-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Alosetron Reduces Time Lost from Work in Women with Diarrhoea-Predominant Irritable Bowel Syndrome: Data from Phase III Placebo-Controlled Clinical Trials

By Jhingran P.   decker C.   Watson M.   Northcutt A.   Ricci J-F.  

Clinical Drug Investigation, Vol. 21, Iss. 12, 2001-12 ,pp. : 843-852

Adis International

Access to resources Recommend Favorite

Pharmacotherapy of systemic lupus erythematosus

By Francis Lisa   Perl Andras  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 9, 2009-06 ,pp. : 1481-1494

Informa Healthcare

Access to resources Recommend Favorite

Neuropsychiatric Systemic Lupus Erythematosus

By  

Current Neuropharmacology, Vol. 9, Iss. 3, 2011-09 ,pp. : 449-457

Bentham Science Publishers

Access to resources Recommend Favorite